MediPharm Labs Corp.
LABS.TO
TSX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 100.45% | 55.83% | 9.23% | 42.92% | -910.31% |
| Total Depreciation and Amortization | -1.57% | -3.31% | -6.82% | 0.69% | 2.26% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 40.36% | -7.35% | 41.02% | -37.13% | -7.32% |
| Change in Net Operating Assets | -95.65% | -134.48% | 24.75% | 405.95% | 108.31% |
| Cash from Operations | 48.42% | -289.90% | 372.01% | 94.27% | 4.64% |
| Capital Expenditure | -4,528.57% | -- | 100.00% | 61.84% | -3.75% |
| Sale of Property, Plant, and Equipment | -- | -- | -100.00% | -88.76% | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -4,528.57% | -- | -100.00% | -89.03% | 10,467.92% |
| Total Debt Issued | -- | -- | -- | -100.00% | -- |
| Total Debt Repaid | 70.65% | 17.49% | -85.83% | -42.86% | 68.30% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -17.39% | 15.00% | -14.89% | 51.61% | -44.64% |
| Cash from Financing | 413.00% | 24.45% | -147.74% | -116.40% | 321.91% |
| Foreign Exchange rate Adjustments | -1.82% | 176.74% | -388.64% | -116.00% | 147.75% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 98.33% | -524.56% | -1.24% | -88.38% | 161.31% |